(CNN) – A single injection of Regeneron anticoagulant cocktail can prevent the covid-19 syntactic between people who have been exposed to the virus, given the company the lunes based on a new three-phase assay.
Regeneron says that it is looking to expand the use of emergency medicine. Currently the anti-cancer cocktail is available in United States to treat infected people with covid-19 of moderate life.
In a new way, the REGEN-COV-named pharmacy reduces the risk of infections by 81%, leaving the company in a state of emergency. The study examined the combination of casirivimab with imdevimab of Regeneron in 1,505 people who had not been infected with the virus, but vivian in the same way hogar than a person who had positive in the four previous days. Each participant receives a dose of the drug or placebo, which has no effects, administered during a subcutaneous injection.
After 29 days, 11 people had received a single dose of 1,200 milligrams of covid-19 with sinuses. También tuvieron la enfermedad con sintomas 59 people who received the placebo. The pharmacy offers 72% protection against the first weekly infections and 93% protection against the following, says Regeneron. The dates have not been published or published in pairs.
The effect of Regeneron among women is ever increasing
Those who receive the anti-cancer cocktail and experiment with a superficial infection will take their symptoms in one week, the company said. This is a comparison with the three week olds who received the placebo.
“In addition to the precautions to be taken to reduce transmission, approximately 10% of people not vaccinated who live with an infected person develop symptomatic infections and do not receive REGEN-COV”, said in a statement the Dr. Myron Cohen, who links the work on monoclonal anti-corruption to the Covid-19 Prevention Red. Cohen also appeared as director of the Institute of Global Health and Infectious Diseases of the University of North Carolina at Chapel Hill.
“If authorized, the REGEN-COV’s subcutaneous administration would be able to control high-altitude traffic offenses involving persons without vacancies, including individual workers and persons living in groups.”
Regeneron says that it buys adverse events in 20% of patients who receive the anticoagulants and 29% of those who receive the placebo. None of the participants who received the drug were hospitalized or terminated in the emergence of covid-19 in 29 days. It was sued in the case of four participants who received the placebo. During the trial, four deaths were recorded, of persons receiving the pharmacy and of individuals receiving the placebo. None of these deaths were caused by covid-19 or by the drug.
Regeneron wants to expand its emergency use authorization
Regeneron said that it was seeking to extend the emergency authorization authorization granted by the Food and Drug Administration (FDA) to include covid-19 prevention and to administer it as a subcutaneous injection. . Currently, the pharmacy is authorized for intravenous administration. This is the longer time and can be part of the reason why the degree of acceptance of the treatment is limited.
The company also announced the lunar that a second phase 3 sequel study was an injection of its anticoagulant cocktail into 204 recently infected asymptomatic individuals. A single injection reduces the risk of developing covid-19 syntactically by 31% in general terms. After the third day, the risk is reduced by 76%. Participants receive the treatment of a placebo, and the test shows that the duration of the symptoms is reduced and the viral levels are reduced between those who receive the anticoagulant cocktail.
Eli Lilly and the company have announced in advance that their therapy with monoclonal anticoagulants, bamlanivimab, will help prevent the covid-19 syndromic infection between residents and senior citizens’ staff. Without embarrassment, the United States Governor informed me that it has not yet distributed the bamlanivimab to its use alone for the purpose of increasing coronavirus variants. Todavía can use the bamlanivimab with the etesevimab, another treatment with monoclonal anticircles developed by Eli Lilly. These Eli Lilly combined treatments work against coronavirus variants.
On the other hand, it has now been demonstrated that Regeneron cocktail is effective against coronavirus pre-existing variants.